Evidence map›Paper›PMID 37127613›Full record

ArticleRetrovirology2023

Attenuation of reverse transcriptase facilitates SAMHD1 restriction of HIV-1 in cycling cells.

Ming-Han C Tsai, Sarah J Caswell, Elizabeth R Morris, Melanie C Mann, Simon Pennell, Geoff Kelly, Harriet C T Groom, Ian A Taylor, Kate N Bishop

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Prime Editing in Dividing and Quiescent Cells.International journal of molecular sciences · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Ming-Han C TsaiRetroviral Replication Laboratory, The Francis Crick Institute, London, UK.
Sarah J Caswell *Macromolecular Structure Laboratory, The Francis Crick Institute, London, UK.
Elizabeth R Morris *Macromolecular Structure Laboratory, The Francis Crick Institute, London, UK.
Melanie C MannRetroviral Replication Laboratory, The Francis Crick Institute, London, UK.
Simon PennellStructural Biology of DNA-Damage Signalling Laboratory, The Francis Crick Institute, London, UK.
Geoff KellyThe Medical Research Council Biomedical NMR Centre, The Francis Crick Institute, London, UK.
Harriet C T GroomRetroviral Replication Laboratory, The Francis Crick Institute, London, UK.
Ian A TaylorMacromolecular Structure Laboratory, The Francis Crick Institute, London, UK.
Kate N BishopRetroviral Replication Laboratory, The Francis Crick Institute, London, UK. kate.bishop@crick.ac.uk.
The Francis Crick Institute · GBDurham University · GBMedical Research Council · GBMRC London Institute of Medical Sciences · GBUniversity of Cambridge · GB

Funding

Cancer Research UK CC2029Cancer Research UK CC2056Medical Research Council CC2029Medical Research Council CC2056Wellcome Trust CC2029Wellcome Trust CC2056
6 · The paper itself

Abstract

backgroundSAMHD1 is a deoxynucleotide triphosphohydrolase that restricts replication of HIV-1 in differentiated leucocytes. HIV-1 is not restricted in cycling cells and it has been proposed that this is due to phosphorylation of SAMHD1 at T592 in these cells inactivating the enzymatic activity. To distinguish between theories for how SAMHD1 restricts HIV-1 in differentiated but not cycling cells, we analysed the effects of substitutions at T592 on restriction and dNTP levels in both cycling and differentiated cells as well as tetramer stability and enzymatic activity in vitro.

resultsWe first showed that HIV-1 restriction was not due to SAMHD1 nuclease activity. We then characterised a panel of SAMHD1 T592 mutants and divided them into three classes. We found that a subset of mutants lost their ability to restrict HIV-1 in differentiated cells which generally corresponded with a decrease in triphosphohydrolase activity and/or tetramer stability in vitro. Interestingly, no T592 mutants were able to restrict WT HIV-1 in cycling cells, despite not being regulated by phosphorylation and retaining their ability to hydrolyse dNTPs. Lowering dNTP levels by addition of hydroxyurea did not give rise to restriction. Compellingly however, HIV-1 RT mutants with reduced affinity for dNTPs were significantly restricted by wild-type and T592 mutant SAMHD1 in both cycling U937 cells and Jurkat T-cells. Restriction correlated with reverse transcription levels.

conclusionsAltogether, we found that the amino acid at residue 592 has a strong effect on tetramer formation and, although this is not a simple "on/off" switch, this does correlate with the ability of SAMHD1 to restrict HIV-1 replication in differentiated cells. However, preventing phosphorylation of SAMHD1 and/or lowering dNTP levels by adding hydroxyurea was not enough to restore restriction in cycling cells. Nonetheless, lowering the affinity of HIV-1 RT for dNTPs, showed that restriction is mediated by dNTP levels and we were able to observe for the first time that SAMHD1 is active and capable of inhibiting HIV-1 replication in cycling cells, if the affinity of RT for dNTPs is reduced. This suggests that the very high affinity of HIV-1 RT for dNTPs prevents HIV-1 restriction by SAMHD1 in cycling cells.

Indexed as

HIV-1Monomeric GTP-Binding ProteinsHumansPhosphorylationRNA-Directed DNA PolymeraseSAM Domain and HD Domain-Containing Protein 1U937 CellsMonomeric GTP-Binding ProteinsRNA-Directed DNA PolymeraseSAM Domain and HD Domain-Containing Protein 1SAMHD1 protein, humanCycling cellsdNTP levelsHIV-1PhosphorylationRestrictionSAMHD1

Identifiers

PMID37127613
PMCPMC10150492
OpenAlexW4367597900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.